Non-Alcoholic Steatohepatitis (NASH) Therapeutics &Diagnostics Market To Witness Lucrative Growth On The Back Of Growing Cases Of Obesity During 2019-2027
Research Nester released a report titled “Non-Alcoholic Steatohepatitis (NASH) Therapeutics & Diagnostics Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global non-alcoholic steatohepatitis (NASH) therapeutics & diagnostics market in terms of market segmentation by therapeutics, by diagnostics and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
The market for non-alcoholic steatohepatitis (NASH) therapeutics & diagnostics is projected to grow by a significantly high CAGR during the forecast period, i.e., 2019-2027. NASH is a fatty liver disorder caused by the accumulation of excessive amount of fat in the liver among people who consume little or no alcohol. The market is segmented by therapeutics, by diagnostics and by region, out of which, the therapeutics segment is further segmented into ocaliva, elafibranor, cenicriviroc, selonsertib and others. Out of these, the elafibranor segment is estimated to observe the highest growth as a result of high efficacy of this drug in serious cases of the disorder.
On the basis of regional analysis, the market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Non-alcoholic steatohepatitis (NASH) therapeutics & diagnostics market in North America is anticipated to hold the leading share on account of rising technological advancements in the region. This can be attributed to the presence of leading market players in the region who are actively involved in research.
Get Sample PDF Copy of this Report
Rising Incidences of Obesity and Diabetes to Influence the Market Growth
According to the World Health Organization, about 1.9 billion adults (above the age of 18) were overweight and out of those, more than 650 million were obese in 2016.
The growing cases of obesity globally might lead to the development of non-alcoholic steatohepatitis, which is anticipated to raise the demand for effective therapeutic and diagnostic method, thereby increasing the market growth over the forecast period. However, the strict regulatory policies by the government and time-consuming process of clinical trials for drugs are estimated to hamper the market growth in the upcoming years.
This report also provides the existing competitive scenario of some of the key players of the global non-alcoholic steatohepatitis (NASH) therapeutics & diagnostics marketwhich includes company profiling ofSiemens Healthcare GmbH (ETR: SHL), Celerion, ZyVersa Therapeutics, Inc., Cisbio, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), BioPredictive, Echosens, Genfit (EPA: GNFT), Enterome and NGM Biopharmaceuticals. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global non-alcoholic steatohepatitis (NASH) therapeutics & diagnostics market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
- Research Nester
- Jacob Dowling